Follow on Google News
News By Tag
News By Location
Follow on Google News
Prioritising Lung Health: How FeNO can help to tackle Lung Conditions, the UK's 3rd Largest Threat
Harnessing the Power of FeNO Monitoring to Combat Lung Conditions – A Vital Step in Addressing the UK's Lung Health Crisis
By: Bedfont Scientific Ltd
Fractional Exhaled Nitric Oxide (FeNO) is a non-invasive medical test that measures the level of nitric oxide in a person's breath. It is a pivotal advancement in asthma care, offering precise insights into airway inflammation. By facilitating accurate diagnoses, personalising treatment plans, and enabling ongoing monitoring of asthma control, FeNO empowers healthcare providers to optimise medication use, reduce exacerbations, and enhance patient engagement. This transformative tool not only improves the quality of life for individuals with asthma but also contributes to more effective, cost-efficient healthcare management, ultimately making a profound impact on the battle against this chronic respiratory condition.
Carol Stonham MBE, RN, MSc, Queen's Nurse, and Policy Lead PCRS, explains, "Making an accurate diagnosis of asthma relies on taking an accurate history and then performing appropriate tests to confirm the diagnosis. Spirometry (a test of lung function) was stopped during the pandemic and has been very slow to restart. FeNO testing provides a valuable piece of the jigsaw to confirm whether a person has asthma (or not). It is a very quick test to perform and most people find it easy to do. The basis of asthma is airway inflammation which is what the FeNO test gives an indication of. It helps confirm a diagnosis quickly and easily and helps the patient better understand their condition and how inhalers work to treat the condition. It helps clinicians make the correct diagnosis in a timely way and get the person onto the correct treatment pathway avoiding unnecessary hospital admission and life-threatening asthma attacks."
Jason Smith, Managing Director at Bedfont Scientific, comments, "As a leading manufacturer of breath analysis medical devices, we understand the pivotal role that innovation plays in enhancing patient care and healthcare efficiency. FeNO testing is a prime example of such innovation. We remain committed to advancing respiratory care and hope that in working towards our mission to make healthcare more accessible, our NObreath® FeNO monitor can help make a positive impact on the lives of individuals living with asthma."
Bedfont Scientific Ltd